TerSera Therapeutics Completes Divestiture of Infusion Specialty Therapies Business to ESTEVE

The sale includes two specialty medications, Prialt and Quzyttir, to the global pharmaceutical company ESTEVE.

Mar. 10, 2026 at 2:54pm

Got story updates? Submit your updates here. ›

TerSera Therapeutics LLC has announced the completion of the previously announced sale of its Infusion Specialty Therapies Business Unit, including the specialty medications Prialt (ziconotide intrathecal infusion) and Quzyttir (cetirizine hydrochloride injection), to the global pharmaceutical company ESTEVE. Under the terms of the transaction, ESTEVE now fully owns Prialt and Quzyttir.

Why it matters

The divestiture allows TerSera Therapeutics to focus on its core oncology and rare disease portfolio, while ESTEVE gains two specialty medications that address significant unmet medical needs in pain management and acute allergic reactions.

The details

Perella Weinberg Partners acted as the financial advisor to ESTEVE on this transaction, while Leerink Partners served as the lead financial advisor to TerSera. The legal counsel for ESTEVE was Arnold & Porter, and Kirkland & Ellis LLP represented TerSera.

  • The transaction closed on March 10, 2026.

The players

TerSera Therapeutics LLC

A biopharmaceutical company with a focus in oncology and rare disease, founded in 2016.

ESTEVE

A global pharmaceutical company headquartered in Barcelona, Spain, with a strong international presence and a focus on delivering highly specialized treatments that address significant unmet medical needs.

Prialt (ziconotide intrathecal infusion)

A non-opioid intrathecal analgesic indicated for the management of severe chronic pain in patients for whom intrathecal therapy is warranted and who are intolerant of or refractory to other treatments.

Quzyttir (cetirizine hydrochloride injection)

A second-generation intravenous antihistamine indicated for the treatment of acute urticaria in adults and children six months of age and older.

Got photos? Submit your photos here. ›

The takeaway

This divestiture allows TerSera Therapeutics to focus on its core oncology and rare disease portfolio, while ESTEVE expands its specialty pharmaceuticals business with the acquisition of Prialt and Quzyttir, two important medications that address significant unmet medical needs.